Butler, Rebecca - University of Wolverhampton - Faculty of Science & Engineering

个人简介

I graduated from the University of Newcastle upon Tyne in 2000 with a MChem (Hons, 1st class) in Chemistry with Medicinal Chemistry. I then went on to complete a PhD at the University of Nottingham in synthetic organic chemistry where I worked towards the total synthesis of Gelsemine under the supervision of Prof Nigel Simpkins. My next role was as a post-doctoral researcher working with Nobel Laureate Prof K. Barry Sharpless at the Scripps Research Institute in La Jolla, California, looking at developing simple, reliable and effective reactions. I then joined Novartis as an industrial Medicinal Chemist in 2006 where I remained until joining the School of Pharmacy, here at Wolverhampton, in 2014. My background means I am an expert in synthetic chemistry, organic chemistry, drug discovery and pharmaceutical chemistry. I thoroughly enjoy teaching these disciplines to the MPharm, BSc Pharmaceutical Science, HND Pharmaceutical Science and MSc degree courses. My experience in industry was working in the fields of respiratory and gastrointestinal diseases. In the early days I was a team leader in the parallel synthesis group. I then moved on to lead several early stage drug discovery projects whilst working towards devising and synthesising new molecules for more advanced projects. I bring these experiences into my teaching especially when focussing on drug design and discovery.

研究领域

Inhibiting methods of antibiotic resistance: Some species of bacteria are able to transfer DNA though a process called competence. This is accelerated when the organisms are put under stress (e.g. during treatment with antibiotics) allowing any enhanced survival traits to be shared with the surrounding population. This survival mechanism ensures a rapid development of resistant populations. The principal goal of my research is to determine whether you could interfere with competence and block the transfer of resistance between bacteria and investigate how this could be used in the development of new antibiotic agents.

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Danahay, H.; Coote, K.; Paisley, D.; Czarnecki, S.; Atherton, H.; Young, A.; Gosling, M.; Abraham, W.; Sabater, J.; Lock, R.; Smith, N.; Stanley, E.; Butler, R.; Bloomfield, G.; Baettig, U.; Collingwood, S. P. Novel dimeric amiloride derivatives: airway efficacy and reduced renal-based effects. Abstracts of Papers, 24th Annual North American Cystic Fibrosis Conference (NACFC). Baltimore MD, October 21-23rd 2010. Baettig, U.; Butler, R.; Smith, N.; Stanley, E.; Oakley, P.; Collingwood, S.; Danahay, H.; Coote, K.; Atherton, H.; Paisley, D. Dimeric modulators of ENaC for the treatment of cystic fibrosis. Abstracts of Papers, 240th ACS National Meeting, Boston, MA, United States, August 22-26, 2010; American Chemical Society: Washington, DC, 2010; MEDI-229. Kwok, S. W.; Fotsing, J. R.; Fraser, R. J.; Rodionov, V. O.; Fokin, V. V. Metal-free catalytic synthesis of 1,5-diaryl-1,2,3-triazoles. Abstracts of Papers, 236th ACS National Meeting, Philadelphia, PA, United States, August 17-21, 2008; American Chemical Society: Washington, DC, 2008; ORGN-020.